SCHEMBL7978141

SCHEMBL7978141

Cn1c(-c2ccc(C(N)=O)cc2Cl)nnc1C(C)(C)Oc1ccc(F)cc1F

nearest known ligand 0.77

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.42
MAPK14 Q16539 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7984903 0.93 HSD11B1 (0.46) HSD11B1MAPK14
SCHEMBL7981874 0.92 HSD11B1 (0.43) HSD11B1
SCHEMBL12671311 0.91 MAPK14 (0.43) MAPK14
SCHEMBL7982202 0.91 HSD11B1 (0.41) HSD11B1MAPK14
SCHEMBL7992178 0.89 RORC (0.41) MAPK14
SCHEMBL12671157 0.89 HSD11B1 (0.43) HSD11B1MAPK14
SCHEMBL12671324 0.89 HSD11B1 (0.40) HSD11B1MAPK14
SCHEMBL7995268 0.88 HSD11B1 (0.39) HSD11B1
SCHEMBL12671290 0.88 HSD11B1 (0.54) HSD11B1
SCHEMBL7980341 0.88 HSD11B1 (0.40) HSD11B1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 HSD11B1 1/4885MAPK14 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.